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I. SUMMARY  
Drug delivery systems (DDS) have the capacity to overcome biological barriers limiting 
the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial 
infections and to prevent the development of bacterial resistance. Despite substantial 
efforts in the field, the current state-of-the-art often fails to achieve those goals, and we 
still observe an increase in bacterial resistance. In the context of drug delivery of 
pulmonary anti-infectives, this work proposes three novel strategies (i) polyplexes based 
on natural polysaccharides (starch, chitosan and cyclodextrin), (ii) self-assembly of 
amphiphilic excipients (farnesylated chitosan, squalenyl hydrogen sulfate), (iii) innovative 
excipient-free nano-assemblies of aminoglycoside antibiotics and farnesyl quorum 
sensing inhibitors. The latter invention allows an exceptional 100% co-loading capacity of 
established antibiotics and innovative pathoblockers without the need of any additional 
excipients. The biofilm eradicating efficacy of such DDS increased 16-fold compared to 
free actives. Finally, the interaction between the DDS and some important pulmonary 
biological barriers, such as biofilm, mucus, and macrophages, was also investigated. The 
knowledge gained in this thesis advances the research in pulmonary anti-infectives 
delivery beyond the state-of-the-art. 
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II. ZUSAMMENFASSUNG  
Drug Delivery Systeme (DDS) haben die Fähigkeit, biologische Barrieren zu überwinden, 
welche die Bioverfügbarkeit inhalierter Antiinfektiva begrenzen. Dies ist wichtig, um 
bakterielle Infektionen zu beseitigen und die Entwicklung bakterieller Resistenz zu 
verhindern. Trotz erheblicher Anstrengungen auf diesem Gebiet werden diese Ziele vom 
derzeitigen Stand der Technik oft nicht erreicht, und wir beobachten immer noch eine 
Zunahme der bakteriellen Resistenz. Im Rahmen der pulmonalen Wirkstofffreisetzung 
von Antiinfektiva werden in dieser Arbeit drei neue Strategien vorgeschlagen: (i) Polyplexe 
auf der Basis natürlicher Polysaccharide (Stärke, Chitosan und Cyclodextrin), (ii) Selbst-
organisations-Partikel aus amphiphilen Hilfsstoffen (farnesyliertes Chitosan, 
Squalenylhydrogensulfat), und (iii) innovative Hilfsstoff-freie Nano-Assemblys aus 
Aminoglycosid-Antibiotika und Farnesyl-Quorum-Sensing-Inhibitoren (QSI). Die 
letztgenannte Erfindung ermöglicht eine bemerkenswerte 100 %-ige Beladung, da sowohl 
das Antibiotikum als auch der Pathoblocker QSI Wirkstoffe darstellen und keine Hilfsstoffe 
mehr benötigt werden. Ein solches DDS verbessert die Biofilm-Elimination 16-fach im 
Vergleich zur Behandlung mit freien Wirkstoffen. Abschließend wurde die Interaktion 
zwischen den DDSs und einigen wichtigen biologischen Lungenbarrieren, wie Biofilm, 
Schleim und Makrophagen, untersucht, was die Forschung im Bereich der Verabreichung 
von pulmonalen Antiinfektiva weiter über den Stand der Technik hinaus vorantreibt. 
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III. ABBREVIATION  
MIC  Minimum inhibitory concentration 
PA   Pseudomonas aeruginosa 
QSI  Quorum sensing inhibitor 
APIs  Active pharmaceutical ingredients 
NPs  Nanoparticles 
DDS  Drug delivery systems 
LC  Loading capacity 
EE  Encapsulation efficacy 
MBEC  Minimum biofilm eradicating concentration 
PLGA  Poly lactic-co-glycolic acid 
PVA  Polyvinylalcohol 
Sq  Squlenenyl Hydrogen Sulfate 
SqNPs Squlenenyl Hydrogen Sulfate nanoparticles 
QSI  Quorum sensing inhibitor 
Pqs  Pseudomonas quinolone signal 
PPGAS Proteose peptone glucose ammonium salt medium 
Tob  Tobramycin 
FDA  US Food and Drug Administration 
Cryo-TEM Cryo-Transmission Electron Microscopy 
CLSM  Confocal Laser Scanning Microscopy 
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1. INTRODUCTION 
1.1. Antibiotics utilities in combatting infection and benefits of local delivery 
Bacteria are present all around us. Most of them, e.g. bacteria in the intestines, are 
harmless and actually helpful; while others can cause infections, once they enter and 
colonize the host. Bacterial infectious diseases in humans, caused by dangerous 
pathogens, e.g. Staphylococcus (1,2), Enterococcus (3), Pseudomonas aeruginosa (PA) 
(4,5), etc., account for a significant proportion of global mortality (6–9). In most cases, 
infected patients are treated with powerful antibiotics that are generally safe in fighting 
infectious diseases. Antibiotics are most preferably administrated orally and/or 
intravenously (10,11). For the treatment of chronic infection, in particular, administration 
pathways with the high doses of antibiotics are frequently employed. Despite good 
therapeutic efficacy against infection, systemic delivery of antibiotics has some 
disadvantages:  
(i) Adverse drug effects as well as cumulative and acute toxicity might occur with 
repeated use of antibiotics at high doses (12,13). The effects are unexpected 
reactions of living systems to antibiotics, e.g. repeatedly administering high 
doses of tobramycin could cause acute/chronic toxicity, a reduction in 
glomerular filtration (14–16). 
(ii) Taking and/or accumulating antibiotics unnecessarily in body sites without 
infection could lead to the development of antibiotic resistance, which further 
causes the impotency of antibiotics against bacteria (17).  
(iii) Most importantly, the poor bioavailability of antibiotics in the infected region, 
which leads to sub- minimum inhibitory concentration (MIC), would cause fast 
resistance development (17,18). 
While adverse drug effects could be avoided by careful prescription of antibiotics 
(17,19), antimicrobial resistance has become one of the most pressing health threats. 
Infections from resistant bacteria are now too common, and some pathogens have even 
become resistant to multiple classes of antibiotics (7,17,20). Table 1 summarizes the 
timeline of the discovery, introduction and observed resistance for antibiotic classes used 
to treat infections. Few new drug classes have been discovered and approved for clinical 
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use since the discovery of penicillin, a member of the ß-lactams class. In most cases, 
antimicrobial resistance has been observed shortly after the discovery of antibiotics, in 
some cases even before the year of introduction (21–23). This problem might be primarily 
caused by incorrect and uncontrolled utilizations of these antibiotics.  
Table 1. Timeline of the discovery, introduction and resistance observed of antibiotics 
(17,22,23) 
Antibiotic class Year of discovery 
Year of 
introduction 
Year of resistance 
observed 
ß-Lactams 1928 1938 1945 
Sulfadrugs 1932 1936 1942 
Aminoglycosides 1943 1946 1946 
Tetracyclines 1944 1952 1950 
Chloramphenicols 1946 1948 1955 
Macrolides 1948 1951 1955 
Fidaxomicin 1948 2011 1977 
Glycopeptides 1953 1958 1960 
Oxazilidinones 1955 2000 2001 
Rifamycins 1957 1958 1962 
Quinolones 1961 1968 1968 
Streptogramins 1963 1998 1964 
Lipopetides 1986 2003 1987 
Diarylquinolines 1997 2012 2006 
 
Amongst the bacterial resistance problems, gram-negative pathogens are 
particularly vexatious. The most severe gram-negative infections and common pathogens 
are Enterobacteriaceae, Pseudomondas aeruginosa (PA), and Acinetobacter, as these 
strains are becoming resistant to nearly all anti-infective drugs that would be considered 
for treatment (7). The same holds true, at least to some extent, for some of the gram-
positive pathogens, e.g. Staphylococcus and Enterococcus (6). The challenges in 
combatting gram-negative pathogens are: (i) they are, in particular, highly efficient at 
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keeping out drugs using their naturally sophisticated cell-wall structure. On the one hand, 
the outer membrane is a barrier for amphiphilic compounds which are usually necessary 
for water-solubility and penetrating the cytoplasmic membrane (24,25). The multidrug-
resistant pumps, in addition, extrude any compounds that cross the outer membrane and 
chemically recognize unrelated molecules based mainly on polarity, preferring amphiphilic 
molecules (26,27). On the other hand, the penetration of hydrophilic actives is restricted 
by the inner membrane (25,28). (ii) Moreover, bacterial mutations which change the 
targeted hits of antibiotics cause inactivation of antimicrobial agents (29)  and the possible 
production of antibiotic-degrading and/or antibiotic-inactivating enzymes which could also 
account for resistance development (20,30). Consequently, these naturally biological 
properties result in tight barriers that help gram-negative bacteria becoming resistant.  
As indicated in Figure 1, the site of action of currently approved antibiotics is either 
located at the bacterial cell envelope or somewhere in the bacterial cytoplasm (9,22,31). 
It is hence important that the antimicrobial molecules reach their target at high 
concentration to possibly overcome the low drug susceptibility. As a result, topical delivery 
of antibiotic, such as e.g. in case of inhalation aerosols for the treatment of pulmonary 
infections, may be postulated to have two major advantages: First, higher drug 
concentrations at the infected body site will lead to more effective bacterial killing and 
decrease the risk of resistance development. Secondly, a reduced exposure at non-
infected body sites will reduce the risk of adverse drug effects, in particular compared to 
systemic drug delivery (32–34).  
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Figure 1. Targets of antibiotics: The three most successful antibiotics hit targets including 
(i) the ribosome (which consists of 50S and 30S subunits), (ii) cell wall synthesis, (iii) and 
DNA gyrase or DNA topoisomerase. Reprinted with permission from Reference (22) 
1.2. Challenges in pulmonary infection treatment and in finding solutions 
Considering pulmonary infection, in particular, Pseudomonas aeruginosa – the 
opportunistic bacterial pathogen, is one of the leading causes of nosocomial infections 
worldwide (35). This pathogen is ranked the second most prevalent among the gram-
negative pathogens reported to the National Nosocomial Infection Surveillance System 
(17,36). Besides causing acute infections, PA is also accountable for debilitating chronic 
lung infection in immunocompromised patients, and is the most commonly isolated 
pathogen in cystic fibrosis sufferers, and is considered the leading cause for morbidity and 
mortality in such patients (37,38). Inhaled therapy has been reported as the most effective 
treatment for those mentioned respiratory bacterial infections due to the locally increasing 
relevance of drug bioavailability (34,37). As a result, inhalation of antibiotics has been 
reported to reduce the frequency of exacerbations, decrease significantly airway bacterial 
density, recover pulmonary function, and most importantly improve quality of life for 
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patients with pulmonary infection (39). However, the current inhaled antibiotics are not 
showing the maximum therapeutic efficacy to eradicate bacterial infection entirely, as they 
still face some limitations and challenges: 
(i) Enhancing drug bioavailability in the lungs by inhalation, however, still requires  
sufficient water solubility (40). This is especially true if we consider that the total 
volume of the pulmonary lining fluid is rather small (approx. 150ml) and 
distributed as a rather thin liquid film, (not more than 30 µm) over the rather 
large epithelial surface area  (140 – 160m2) (41–43). At the same time, the 
relative low potency of inhaled anti-infectives requires the delivery of rather high 
doses (up to several 100mg) in comparison to e.g. broncholdilators or 
corticosteroids for the inhalation therapy of asthma or COPD. For this reason, 
the water solubility of inhaled anti-infectives is essential and highlights the need 
to design strategies to enhance water solubility significantly. This objective is 
the subject of ongoing discussions in the context of a pulmonary 
biopharmaceutics classification systems (PBCS) (40).  
(ii) While increasing drug solubility in the pulmonary lining fluid is a problem on its 
own for poorly water-soluble antibiotics, it is also essential to maintain the 
concentration of drug in this compartment above the MICs as long as possible 
(44). This again, however, is restrained by systemic absorption across the air-
blood barrier, in addition to the efficient clearance mechanisms of the lungs, 
e.g. mucociliary (45) and macrophage clearance (46). Furthermore, the 
repeated use of high doses of antibiotics without controlled release and 
nonspecific targeting at the lung site would also induce toxicity to healthy lung 
cells (47,48). 
(iii) In the past years, clinical studies have revealed that the current inhaled 
antibiotic formulations could only be fully proficient in termination of the spread 
of the pathogen and reduction in the demolition of the airway tissues (49). As a 
gram-negative pathogen, PA is naturally resistant to many antibiotics due to the 
reasons mentioned above. Moreover, pulmonary PA infections are complicated 
by the formation of PA biofilms. The latter are multiple-cellular surface-attached 
and spatially oriented bacterial communities (described in Figure 2), composed 
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of bacterial cells in high metabolic outer regions and low metabolic/persister 
central regions which are crucially accountable for the development of PA 
resistance (50–52). As discussed in Figure 1, the antibiotics exert their 
mechanism of actions most efficiently on metabolically active bacterial cells 
(22); as a result, the persister bacterial cells in the dormant regions of biofilms 
foster the survival of biofilm and the recurrent infection. Furthermore, the 
structure of extracellular matrix in a biofilm, which is mainly composed of 
alginate, extracellular polymers, lipids and DNA, displays a significant barrier to 
the penetration of antimicrobial agents (53–55). For instance, the effectiveness 
of aminoglycosides, in particular tobramycin – a positively charged antibiotic, 
which is widely used as a first-line therapy in the cystic fibrosis infections – is 
provenly decreased by the strong interaction between the drugs molecules and 
the biofilm materials, causing slow and incomplete penetration of the drug into 
the biofilm matrix (55,56). Besides, the low pH in the surrounding infected 
environment and in the biofilm would promote the drug molecules, e.g. 
ciprofloxacin, to interact with alginate by charge interaction, which further 
causes the remarkable reduction in drug concentration at the action site (57). 
Consequently, the antibiotic concentrations will be hardly above the MIC, 
promoting mirco-environmental pressure and further fostering the biofilm 
formation, as well as generating drug-resistant bacterial sub-populations. 
 
 
 
Figure 2. Biofilm development (A) Planktonic bacteria attach reversibly to surface (B) 
irreversible adhesion to the surface, and effect of quorum sensing begins (C) Maturation 
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phase: micro colony formation (D) extracellular matrix synthesis and biofilm maturation to 
reach maximum thickness (E) Dispersion/Migration of planktonic bacteria from biofilm 
matrix. Reprinted with permission from Reference (50). 
 
In the pulmonary air space, the epithelia are covered with a layer of mucus 
which has hydrogel-like structure mainly composed of water, mucins 
(glycoproteins), DNA, proteins, lipids, and cell debris (58). This mucosa 
represents the first landing spot and the primary site of entry for pathogens to 
interact with and colonize the host tissues (59). Despite its barrier functions, 
mucus only insufficiently protects the exposed epithelia from external threats 
like pathogen colonization (59,60). Neutrophils, macrophages, dendritic cells, 
natural killer cells, e.g. T and B lymphocytes, glycoproteins, effector peptides 
and proteins, e.g. defensins, complement, C-reactive protein, as well as pro-
inflammatory chemokines and cytokines, which are of the innate and adaptive 
immune systems, are usually contained in mucosal epithelia to serve as host 
immune response to infections (59). Once the pathogen, however, surpasses 
these naturally defending systems, the mucosa is in part hypothesized as a 
possibly superior environment for bacterial infection and resistance 
development (61). Notably, the thick and sticky mucus build-up in the lungs 
makes cystic fibrosis sufferers more apposite to the fast development of 
bacterial infections that could last for a long time. Although it is recognized in 
the clinic, the understanding of mucosal biofilm structure and behaviors of 
bacteria persist in mucosal biofilms are not fully revealed. Nevertheless, it has 
been recognized that mucus-embedded biofilms persist for decades and cannot 
be wholly eradicated (62). One might simply hypothesize that the naturally 
negatively charged matrix of mucus in addition to the extracellular matrix of 
biofilm would form a physically stronger barrier which might highly prohibit the 
penetration of antibiotics to the site of action (56,62,63). As a result of such 
embedment, the mucosal biofilm is an even harder-to-treat infection that 
conventional inhaled therapy could not completely eradicate.  
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(iv) Despite a variety of available potent antibiotics, the attraction of clinical benefits 
as well as the aggressive therapeutic development and drug discovery, there is 
only a limited number of antibiotics that are approved as inhaled therapy for the 
treatment of pulmonary infections (34,44,64). Considering PA infections 
associated in cystic fibrosis patients which are considered as a severe disease, 
there are just four inhaled antibiotics which are approved for clinical use in 
Europe, including colistin (and its prodrug), tobramycin, levofloxacin, and 
aztreonam (their structures are depicted in Figure 3) (64,65). Moreover, there 
is just a finite number of drugs undergoing clinical trials for treatment pulmonary 
infections in general. This slows down the progress in developing novel anti-
infectives (22), although the fact that clinical studies need tremendous efforts, 
supports and time, is accepted. As a consequence, it remains challenging to 
combat with infection considering the limited portfolio of alternative antibiotics 
once pathogens become resistant to one drug (64). 
 
 
 
Figure 3. Structure of approved inhaled antibiotics for treatment of pulmonary infection in 
cystic fibrosis patients in Europe: colistin, tobramycin, levofloxacin, aztreonam. 
Ciprofloxacin has been being studied in clinical trials. 
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Having considered the recognized challenges and knowledge gaps in combatting 
antimicrobial resistance pathogens, scientists have proposed and been working on 
different approaches to discover effective strategies to overcome or at least slow down 
the resistance development, which in overall means to improve the life quality of the 
patients. There are significant efforts in finding new antimicrobials and strategies for 
therapeutic improvement of the approved antibiotics which are summarized in Figure 4.  
 
 
 
Figure 4. Flow chart indicates different strategies for combatting antimicrobial resistance, 
and the needs of delivery strategies.  
On the one hand, the new antimicrobials have been discovered by using a variety 
of advanced approaches, including phage therapy, immune therapy, and vaccination, as 
well as discovery and synthesis of new anti-infectives based on newly discovered and 
existing platforms. In general, these pathways mainly aim to obtain more potent agents 
which could have better drug bioavailability at the site of action by better penetration 
through the bacterial cell wall and the surrounding environmental barriers, e.g. biofilm, 
cellular membrane (22,66–69). These discovered actives also aim to have species-
Strategies for combatting antimicrobial resistance
Possible platforms for 
discovery of new antimicrobials
Immune therapy & vaccination Combined therapy based on 
existing anti-infectives
Phage therapy
Possible platforms for 
therapeutic improvement
Discovery of new anti-infectives
Prodrug approach
Enhancing the drug bioavailability
at the site of infection
New antibiotic analogs
New antibiotic discovery
Anti-infective: virulence factors
Antimicrobial peptides
Needs of delivery strategies
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specific targets that would be selective and sensitive to specific bacteria, and be safe to 
the healthy tissues, in agreement with the pioneering concept postulated by Erlich in 1906 
who had referred to targeted drugs as ‘magic bullets’. Nevertheless, as stressed by R. 
Duncan (1997), the development of targeted drugs is inevitably lengthy process, and 
breakthroughs are more frequently a dream rather than reality’ (70). One of the important 
reasons is that there is a limited number of exploited targets, out of nearly 200 conserved, 
vital proteins in bacteria, has been discovered and considered effective targeting for 
antibiotics (22), described in Figure 1.  
Despite the intensive focus on the discovery of new antimicrobials, the therapeutic 
value of such agents still has to be demonstrated clinically (22). And it is true that there is 
a very finite prospect of successfully discovering and bringing an antimicrobial from 
leading agent identified in preclinical studies (22). In most of cases, the antimicrobials 
have been designed to eradicate infection by interfering with bacterial growth, which 
intrinsically will put stress on bacteria and therefore might quickly lead to resistance 
development (71). Consequently, the approach would again have to deal with the existing 
challenges recognized from approved antibiotics. Taking a different view, the concept of 
pathoblocker such as e.g. quorum sensing inhibitors (QSI) may be considered as a 
promising strategy to overcome the growing and challenging resistance problem. The QSI 
would not interfere with bacteria growth and therefore avoid the stress caused by 
antibiotics that leads to resistance. Instead they just would prevent the biofilm formation 
by inhibiting the bacterial communications via quorum sensing and signal transduction 
systems which are suggested to mediate drug resistance (72). Upon being treated with 
QSI, the biofilm structure would not grow strongly. The bacteria would thus be prevented 
to form persister cells, and be more sensitive to antibiotics. The approach has shown 
some promising results in previous studies, especially when combining with approved 
antibiotics the efficacy against bacterial biofilm has been increased significantly (73,74). 
Still, however, most of the discovered QSI compounds have poor water-solubility which 
limits the bioavailability and thus therapeutic efficacy of these molecules, and also 
impedes their administration, also by way of inhalation (75). 
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On the other hand, being attracted by the obvious clinical benefits of the availably 
approved antibiotics, scientists have been trying to improve the therapeutic efficacy of 
those compounds to overcome the bacterial resistance. Based on the approved agents, 
prodrugs which would only act in the targeted site have been synthesized (22,76). This 
approach has been expected to prevent the toxicity caused by the antibiotic itself, like e.g. 
for colistin and some of its prodrugs (77,78). The reduction in resistance development 
has, however not been convincingly proved. Alternatively, combining antibiotics which 
would hit different targets is hypothesized to overcome the significant antibiotic tolerance 
that individual antibiotic therapy often fails, is another strategy to eradicate a broad 
spectrum (79–82). Moreover, to enhance the drug concentration directly at the action site, 
breaking the biological barriers such as mucus by using mucolytic N-acetylcysteine has 
been also considered and successfully applied (83,84). These approaches require the 
concurrent administration and action of such compounds. However, these aims remain 
challenging to achieved due to the differences in physiochemical properties and 
pharmaceutical characteristics of the actives pharmaceutical ingredients (80). 
Taking together the discussions above, there are a variety of approaches, progress 
and remaining limitations in the discovery and development of strategies against antibiotic 
resistant bacterial infection. Either focusing on the discovery of new antimicrobials or 
improving the therapeutic effects of the available, approved compounds, one crucial factor 
to move forward in combating bacterial resistance is enhancing the bioavailability of the 
drugs at the infection site. Thus, there is a need for efficient delivery strategies which could 
accomplish the correctly sustained distribution of antimicrobials in the infected regions at 
a high concentration.  
1.3. Drug delivery systems aim for pulmonary infections treatment 
1.3.1. Advantages of drug delivery systems in pulmonary infections treatment 
As discussed above, the pulmonary delivery of antibiotics has shown increasing 
relevance for the treatment of respiratory bacterial infection compared to the conventional 
administrations of antibiotics, including oral and intravenous administrations. The method 
also offers less risk of systemic serious adverse effects and an improvement of the 
antibiotics bioavailability and bio-distribution in the targeted lung sides. The hypothesis 
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seems to be promising, but the pulmonary delivery of drugs is in general challenging due 
to the mentioned reasons. To address those problems, appropriate formulations of drugs 
with pharmaceutical excipients, which are later considered as drug delivery systems 
(DDS), are hence required. 
The drug formulating strategies are usually defined depending on the 
physiochemical properties of drug molecules and their intended application. In general, 
the delivery systems would first address the limitations in therapeutic efficacy observed in 
many currently used and discovered active pharmaceutical ingredients (APIs) which are 
due to (i) the poor water-solubility, (ii) problem in delivering the molecules to biological 
environment (e.g., reduced in vivo half-life/stability), and (iii) the potential to induce high 
toxicity (85,86). In the field of drug delivery, nanotechnology has particularly attracted 
remarkable attention, which means to engineer drug-loaded nanostructures and 
nanomaterials with a size range between 10 and 1000 nm for the improvement of APIs 
performance (87). As a consequence, this “tiny-technology” would increase the water-
solubility of poorly water-soluble drugs, and also protect unstable molecules from 
degradation in the presence of enzymes, as well as minimize the possible adverse effects 
by encapsulating the drugs into small vehicles (88). Considering pulmonary 
administration, the utility of nanotechnology for antibiotics delivery would not only increase 
the drug solubility of poorly water-soluble drugs in the thin pulmonary lining fluid, but also 
prevent the fast drug-clearance. The latter is of particular impact for hydrophilic drugs due 
to the systemic absorption across the air-blood barrier, and moreover the efficient 
clearance mechanisms of the lungs, including mucociliary clearance and alveolar 
macrophages (89). Thus, the drug bioavailability at the site of infection is improved. The 
binding properties of drug molecules to the pharmaceutical excipients and thus release 
from the nanocarriers would be tuned by linkages between drug molecule-materials, 
chemically designing the structure of the excipients, and method of preparing the drug-
loaded carriers. In addition to the achievement of temporal and spatial site-specific 
delivery, nanomedicine hence allows the administration of a sustainably sufficient dose in 
a controlled release manner (90–92). Especially for the delivery of antibiotics, their 
concentration would be maintained above the MIC values for longer time (44). The design 
and engineering of excipients used in nanomedicine would further offer better affinity 
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towards the bacterial cell envelope. More importantly, despite the controversy and lack of 
clinical evidence, nanomedicine is believed to improve drug transport across biological 
barriers, e.g. biofilm and/or mucus, to deliver drugs more directly to the persister bacteria, 
which would possibly improve their antibacterial activity, and reduce the potential of 
bacterial resistance and recurrent infections (93,94). Lastly, nanomedicines could be 
designed to efficiently deliver established or emerging drug molecules, or even a 
combination of different functional actives in a targeted manner, which is so-call 
multifunctional carrier systems (an example of the carrier structure is shown in Figure 5). 
This flexibility of nanotechnology in drug delivery offers additional possibilities to combat 
bacterial resistance, and in particular pulmonary bacterial infections. The advantages of 
using DDS is summarized in Figure 5. 
 
 
 
Figure 5. Advantages of drug delivery systems. 
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1.3.2. Requirements in preparation of drug delivery systems 
The approach of using DDS is to improve the therapeutic efficacy of drugs which 
would further aim to transfer the technology closer to clinical use. Thus, it is important to 
firstly develop strategies that have capacity to improve drug bioavailability, which means 
that the carrier systems can encapsulate drug at high loading capacity (w/w ratio, the 
calculation is shown in equation (i)) and good encapsulation efficacy (the calculation is 
shown in equation (ii)). Furthermore, the carrier systems should also allow the 
simultaneous delivery of diverse active cargoes which would provide complementary 
therapeutic effects (95,96). The flexibility for further modification of the systems should 
also be enabled to potentially enhance the interaction and affinity with the targeted sides 
of infections (88,97). Those kinds of functionalization are also good approaches to even 
more reduce the risk of adverse effects. Most importantly, the materials that are used for 
the preparation of such carriers should be nontoxic and biodegradable which are cleared 
after it fulfilled the function in vivo (83,98–102). As have been discussing, there are many 
challenges in pulmonary delivery of drugs, and using DDS would help to solve those 
pronounced problems. As a consequence, the more sophisticated systems should be 
developed to fulfill all requirements that would finally help improve the therapeutic effects 
of drugs. Although nanotechnology is in general one such avenue – a scientifically diverse 
discipline that encompasses engineering, materials science, physics, chemistry, and the 
biological sciences, its use in the field of drug delivery has been remarkably developing, 
which has proposed plenty of strategies for preparing DDS (103,104). Remarkably, the 
focus in this field has been shifted from making just simple drug-loaded carriers to 
engineer the carriers with new desired properties to better control the delivery profile and 
overcome biological barriers, have specific targeting action and even for imaging, thus 
rendering them attractive for treating applications. However, the number of 
nanomedicines that are marketed is indeed finite, as those sophisticated systems often 
fail to move closer to preclinical studies due to the complexity of the producing procedure. 
In addition to that, the reproducibility of multi-functionalization of the carrier system, which 
would offer a better therapeutic efficacy, is hard to achieve at large scale production. And 
it is no doubt that the price for such advanced development could not be competitive 
compared to the established therapy (105,106). Figure 6 depicted the general 
INTRODUCTION	
	
	
23	
	
requirements in the development of DDS. To have good DDS, there should be a 
compromise between the pharmaceutical and engineering requirements in the selection 
of materials. Thus, the search for the pharmaceutical excipients used in DDS which qualify 
all requirements still remained challenging. Especially, it is even harder in the 
development of anti-infectives delivery systems, as the high dose of such drugs are 
frequently required (106). Therefore, it is necessary to have the facile strategies that use 
conventional materials for developing high antibiotic loading capacity carrier systems, and 
that sill allows the further modification for the advanced therapeutic improvement. 
The advantages of DDS would profoundly improve the therapeutic effect once the 
drug loading capacity of such carriers is achieved at a high level. Having in mind that the 
active cargos should be delivered not materials, the optimization of drug loading capacity 
is critical to consider in the process of developing DDS. 
The drug loading capacity (LC%) and encapsulation efficacy (EE%) are calculated 
as the equations below: EE% =	𝑊𝑒𝑖𝑔ℎ𝑡	𝑜𝑓	𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑	𝑑𝑟𝑢𝑔	𝑖𝑛	𝑁𝑃𝑠𝐼𝑛𝑖𝑡𝑖𝑎𝑙	𝑤𝑒𝑖𝑔ℎ𝑡	𝑜𝑓	𝑢𝑠𝑒𝑑	𝑑𝑟𝑢𝑔		 	x	100									(i) 
 LC% =	𝑊𝑒𝑖𝑔ℎ𝑡	𝑜𝑓		𝑑𝑟𝑢𝑔	𝑖𝑛	𝑁𝑃𝑠𝑊𝑒𝑖𝑔ℎ𝑡	𝑜𝑓	𝑁𝑃𝑠	 	x	100								(ii) 
“Weight of NPs” was calculated as (Weight of NPs = Weight of polymeric materials 
+ Weight of encapsulated drug in NPs). 
On the one hand, the EE% indicates the efficiency of the drug loading procedure, 
which is important in planning the amount of drug used in loading procedure so that the 
amount of un-loaded and thus wasted drug would be minimized. On the other hand, the 
LC% demonstrates the actual drug amount in comparison to the actual total weight of the 
whole DDS, which is needed in calculating the dose when using the drug-loaded DDS in 
treatment. Notably, the LC% is crucial in pulmonary delivery, since only a finite dose can 
be applied to the lung, e.g. by inhalation of dry powder. While EE% is rather easy to 
maximize by optimizing the initial in-put drug amount, the achievement of LC% at high 
value remains challenging resulting in less chance to move on in preclinical studies. Thus, 
LC% is one of the first factors that need to be improved to obtain a good DDS. 
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Figure 6. General requirements in development of drug delivery systems. 
1.3.3. Recent development of anti-infective delivery systems for pulmonary 
infections treatment 
Recognizing the advantages of local delivery, inhaled antibiotic therapy has been 
used to treat chronic respiratory infection since the 1940s (107). The earliest formulation 
was not explicitly designed for inhalation, so it caused significant bronchial irritation. A 
major advancement of such development took place in 1997, when the FDA first approved 
a designed formulation for inhalation, which was tobramycin for use in PA infected patients 
with cystic fibrosis (108,109). The approach has shown significant clinical benefits. 
Subsequently, dry powder formulations, which are kinds of DDS, were developed to 
enhance the delivery of antibiotics to the lungs sites (110). This strategy allowed to  
notably decrease the dose of antibiotic per application (111). This development has been 
considered as a very promising approach to have a safer profile when using antibiotics 
and also avoid the fast resistance development. And the interest in the use of such 
formulation has been not only for infections associated with cystic fibrosis, but also for 
other lower respiratory tract infections (112,113).  
In this thesis, only respiratory PA associated infection and strategies for the 
treatment of such diseases will be focused on. The most common dry powder inhalation 
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antibiotics considered for PA infection are tobramycin (110) and colistin (113). The dry 
powder form of ciprofloxacin has also been investigated in a phase III randomized study 
and appeared to be favorable for the treatment of pulmonary PA infections (114). 
However, in many severe and resistant infected cases, e.g. infections associated with 
cystic fibrosis patients, the efficacy of the dry powder, in particular tobramycin dry powder, 
is still limited by the ability to achieve sufficient concentration levels at the site of infection 
(115). It is noted that the drug loading capacity of the dry powder antibiotic, in particular 
in the case of tobramycin, is really high at ~50% (w/w ratio) (116,117). Hence, this 
consequence can be attributed by rapid clearance of the drug as well as the poor mucus 
and biofilm penetration and inactivation of the drug through binding interactions in these 
environments. Those problems could be explained by the typical particles size of dry 
powder antibiotics produced mostly by spray-dry technology which is frequently in micron 
range (1-10 µm) and not uniform (116). Therefore, novel strategies for improving antibiotic 
delivery could enhance the activity of those vital antibiotics. In addition to developing the 
delivery systems for those available, potent antibiotics, there are chances to combine into 
the delivery systems novel anti-infectives by taking advantages of recent drug delivery 
techniques to even better enhance the therapeutic effects of the established antibiotics. 
As discussed above, although nanotechnology has been aggressively pursued in 
drug delivery, simple approaches for drug delivery should still be advanced with the aim 
to achieve higher and faster rate of translation into clinical use. There is an uncountable 
number of studies aiming to prepare the vital antibiotics loaded carrier systems. The 
popular carrier systems used are (i) liposome (118,119); (ii) microemulsions and 
nanoemulsions (118); (iii) solid lipid NPs (23,120); (iv) polymeric particles, including 
particles made from synthetic polymers, e.g. silica particles, poly lactic-co-glycolic acid 
(PLGA) particles, as well as made from natural polymers, e.g. chitosan derivatives, 
alginate (89,121–123). Metallic NPs, e.g. silver, gold, titanium dioxide NPs, are known to 
have antimicrobial properties, and also widely developed and applied to prevent the 
bacterial colonization and eradicate biofilm infection (117). Considering the long-term 
administration, especially for inhaled therapy, these non-biodegradable materials are, 
however not preferred. Table 2 summarizes representatives of antibiotic-loaded liposomal 
and particulate systems that are developed for inhaled therapy to treat PA associated 
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infections. There is a vast number of publications concerning the preparation of antibiotic-
loaded carrier systems, in which the EE% was reported carefully. LC%, one of the 
essential factors deciding the success of a DDS, was, however not explicitly reported. 
Thus, there are just some representatives shown in Table 2 with LC% presented as the 
maximum obtained values in the corresponding publications.  
Table 2. Summary of representative delivery systems of inhaled antibiotics aimed for PA 
infections treatment. Drug, production method, major excipients and loading capacity 
(LC%) are highlighted. LC% is presented as the maximum value reported in the 
corresponding publications. 
Summary of representative liposomal delivery systems of inhaled antibiotics 
aimed for PA infections treatment 
Drug 
Production 
method 
Major excipients LC% Ref. 
Amikacin 
(Arikace®) 
N/A(a) N/A ~60% (124) 
Tobramycin 
Membrane 
extrusion 
1,2-Distearoyl-sn-glycero-3-
phosphocholine, cholesterol 
~60% (125) 
Ciprofloxacin 
(Lipoquin® 
and 
Pulmaquin®) 
Membrane 
extrusion 
Polysorbate 20, 0.4% (w/v), 
hydrogenated soy 
phosphatidylcholine, 
cholesterol 
16-
33% 
(126)(127) 
Colistin  
Sonication/ 
Membrane 
extrusion 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, cholesterol, 
1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine  
12-
55% 
(128) 
Summary of representative polymeric delivery systems of inhaled antibiotics 
aimed for PA infections treatment 
Drug 
Production 
method 
Major excipients LC% Ref. 
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Levofloxacin 
Lipid-coated 
nanoparticles via 
an 
emulsification-
solvent-
evaporation 
method followed 
by spray drying 
PLGA, PVA, 
phosphatidylcholine, L-
leucine 
<1.1% (129) 
Tobramycin 
Nanoparticle 
suspension by 
the 
emulsion/solvent 
diffusion method 
followed by spray 
drying 
PLGA, PVA, chitosan, 
alginate, lactose 
<2% (130) 
Tobramycin Polyplexes Alginate, chitosan <9% (115) 
Gentamicin 
Emulsion/solvent 
diffusion 
PLGA, PVA <2% (131) 
Ciprofloxacin Polyplexes 
Chitosan, tripolyphosphate 
of sodium salt 
<5% (132) 
 
(a)N/A: not available 
 
 It is undoubted that liposomal carrier systems which could be prepared by 
conventional techniques actually capable of loading the high percentage of antibiotic, 
at maximum nearly to 60%. Such loading capacity is promising to improve the antibiotic 
bioavailability in the targeted sides which as a result benefits the therapeutic effect 
against infections. In addition to the better bioavailability, reported data pronounces that 
the adverse effects caused by antimicrobials in the lungs cells significantly reduced 
when using the drug loaded liposomes compared to free drugs inhaled as a solution. 
However, the antibiotic loaded liposomal formulation could only improve the therapeutic 
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effect slightly considering the decrease in MIC values. The retention time in the infected 
regions was not remarkably improved, which could be explained by the fast release of 
antibiotics from the liposomal formulation. In most cases, the cumulative antibiotics 
reached 100% in a biologically relevant medium in a short time ranged from 10 minutes 
to 2 h (133,134). This burst effect is often seen in most of the drug-loaded liposome 
due to the non-specific binding of drug molecules and liposomal excipients. A further 
modification, e.g. surface coating and/or crosslinking, would possibly prevent such 
problem. The approach in turn sometimes affects the stability of the system and actually 
complicates the mean of this conventional method (135,136). The same holds true for 
the antibiotic-loaded systems produced from microemulsions and nanoemulsions as well 
as solid lipid NPs technologies, but the LC% in these cases are not as high as ones 
obtained from liposomal formulations. 
 Polymeric NPs appear to be promising candidates to better prevent the burst 
effect as the binding between drug and excipients either covalently or noncovalently 
could be flexibly tuned by changes of polymer properties and particles preparation 
methods. The approach does show better controlled release profile of encapsulated 
drugs. Furthermore, polymeric carrier system would allow further modification with more 
desired properties of delivery systems, thus rendering them attractive for 
nanomedicines. Nevertheless, the LC% is a considerable limitation when using these 
DDS, which is in most cases lower than 5% (133). Consequently, the DDS based on 
this technique has still mostly remained in research. 
Furthermore, the particle size is also a design parameter which can affect 
therapeutic effect of DDS. The importance of LC% is recognized, so optimizing such 
value might also increase the size of the carrier systems. Thus, while true nanomaterials 
are considered smaller than 100nm in size, the so-called submicron range (i.e., 100 – 
900nm) is defined as size range for nanomedicine, which appears to provide the better 
opportunities to carry higher amount of drug (87). For such reason, the maximum 
recorded drug LC% in liposome and polymeric particulates usually have the sizes larger 
than 500nm, which is actually not favorable for crossing biological barriers, but at the 
same time becomes the target for the natural clearance mechanism (87,137). Thus, the 
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site-specific delivery of therapeutics will remain a distant reality unless drug carrier 
systems cross through the biological barriers, which is, in the case of extracellular 
infections, biofilm. Such biological barrier significantly contributes to the fails of those 
DDS. 
Most importantly, those single antibiotic loaded carrier systems could in general 
not decrease the dose of antibiotic used in the treatment of infection, in some cases the 
dosage should even be increased. Thus, the recent status of antibiotic delivery would 
just decrease bacterial susceptibility, but it is still challenging to overcome the bacterial 
resistance development. Despite the pronounced limitations, the developed carrier 
systems have shown promising results in decreasing the viability of bacteria in biofilm, 
and such efficacy is better than the treatment with free antibiotics. Thus, there is the 
need to develop the better antimicrobial delivery systems for combatting with bacterial 
infections. 
Taking advantages of DDS, the advanced development in nanotechnology, and 
the discovery of novel anti-infectives, some researches have been focusing on 
advancing the carrier system and/or developing strategies for efficiently co-delivery of 
diverse active agents, which consequently achieve the enhancement in complementary 
therapeutic effects. Among many research, there are some that could be highlighted 
including: (i) polymyxin B containing polyion complex nanoparticles in which polymyxin 
B was complexed with different molecular weight poly(styrene sulphonate), shown 
10,000 times improvement in inhibitory effect against PA (138); (ii) the combination of 
tobramycin and mucolytic agent, dornase alfa (DNase) were achieved in a chitosan-
alginate polyplexed system, such simultaneous delivery of the two active compounds 
improved the therapeutic effect of tobramycin in the contact with cystic fibrosis sputum 
(115); (iii) Bismuth-ethanedithiol, a biofilm reducer, and aminoglycoside tobramycin 
were co-loaded in a liposome system which shown a decrease of CFU counts in vivo in 
comparison to ones treated with free drug (125); (iii) Incorporation of farnesol, a natural 
quorum sensing inhibitor, and ciprofloxacin in a liposomal formulation exhibited a very 
interesting outcome. The minimum biofilm eradicating concentration (MBEC) value 
obtained by using the co-delivery system was reported at 0.128 µg/mL of ciprofloxacin 
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which is actually same as the reported MIC value of ciprofloxacin for planktonic bacteria 
at 0.125 µg/mL (73). The results of these studies were promising and shown the 
possibility to reduce the use of antibiotic when applying them in a combination with 
other complementary agents, which is important to further prevent antimicrobial 
resistance. However, more relevant in vivo data which proves the complete infection 
eradication has been not reported yet. Furthermore, despite having a promising concept 
to combat with bacterial biofilm, those formulation characteristics, including the 
particulate characteristics (importantly the size and charge surface) and drug release 
profile, were actually not best optimized. Thus, such specific research area in 
developing nanotherapeutics has been recently attracting more attention in combatting 
resistant bacterial biofilm, which will be focused on this thesis. 
1.3.4. Interaction between drug delivery systems and pulmonary biological barriers  
Having discussed that the successful accumulation of either drug molecules or 
nanotherapeutics specifically at the diseased sites, thus restricting effective responses 
in disease processes is prevented by biological barriers. Particularly considering 
respiratory bacterial biofilm infection, the means of biological barriers that limit the drug 
transport are bacterial cell membrane, biofilm, mucus, mucosal biofilm, and the 
pulmonary immune regulators (139). The crucial biological barriers to inhaled DDS are 
depicted in Figure 7. As the ultimate aim is to treat biofilm infection and overcome the 
antimicrobial resistance, the antibiotic drug molecules should travel through all 
aforementioned barriers and be accumulated either in the bacterial membrane or in 
bacterial cytoplasm. However, the free drug molecules usually fail to fully accomplish 
the aim, the DDS is thus needed. Although considerable research efforts have focused 
on incorporating multiple surface functionalities and moieties within the overall NP 
design and preparation, many of these strategies fail to successfully address these 
barriers successfully. A reinterpreting of conventional drug delivery systems is thus 
needed to successfully negotiate these impediments to a single carrier system. By 
successively understanding and addressing each of these biological barriers, 
appropriate design features of drug delivery systems could be rationally incorporated 
that will create a successful generation of particulate-based drug delivery systems.  
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In drug delivery system features design, particulate size, surface properties and 
morphology and particles shape of are frequently tuned to aim for better penetration 
through the biological barriers (93). Ideally, the particles would successfully penetrate 
through such obstacles would have the characteristics, including (i) small size, the 
smaller the better for the transport. The destiny of the particulate system is to carry drug 
which as a consequence could not be too small, so the appropriate size range is in most 
of the cases considered below 200nm; (ii) anti-fouling surface which is covered with 
polyethylene glycol (PEG) or zwitterion materials; (iii) smooth surface morphology. With 
these requirements, spherical PEGylated NPs with size range below 200nm are known 
to have a high rate in transportation through biological barriers including mucus and 
biofilm. Moreover, the small size range and neutral charge surface would also be 
responded slowly by the immune systems, the systems would hence have a prolonged 
in vivo residence time (93). However, having PEGylated or zwitterionic surface would 
simultaneously lose or decrease the potential of drug loading on the surface. In addition 
to that, the small size range would limit the drug loading capacity in the core side of the 
particles. Hence, the design of biological barriers penetrating NPs should find a 
compromise with the loading capacity of such systems. 
Considering more carefully, the mucosal epithelia, e.g. airway epithelia, are 
covered with a retentive viscoelastic mucus layer, a three-dimensional macromolecular 
network with the ability to entrap and remove NPs in a size-dependent manner and 
mucociliary clearance (58,140). Additionally, such mucus layer together with 
biofilm/mucosal biofilm could also interact and adsorb the particles as well as molecules 
via electrostatic interactions (58). Instead of fighting and overcoming these natural 
characteristics of mucus and biofilm/mucosal biofilm, those have been exploited as a 
method to prolong the residence time of DDS, in particular for positively charge NPs, 
e.g. chitosan based NPs as DDS in mucosal surface (141,142). The natural clearance 
is, in turn, inevitable when applying foreign particulate materials in vivo. The clearance 
rate is another important factor which decides in vivo residence time of the DDS. For 
those DDS used the as inhaled therapy, the key regulators of pulmonary immunity, e.g. 
lung macrophages and dendritic cells, should be carefully taken into consideration 
(137,143). Therefore, the dependence of macrophage uptake efficiency on particle size 
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and surface properties should be investigated and predicted in vivo. Thus, the future 
use of the drug-loaded carrier systems would be accurately recommended.  
 
Figure 7. Biological barriers to inhaled anti-infective-loaded drug delivery systems.
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2. RESEARCH STRATEGIES, WORKING HYPOTHESIS AND AIMS OF 
THE THESIS 
The overarching purpose of this thesis is to develop the existing strategies further 
and to discover novel platforms for anti-infective DDS aiming for the treatment of 
pulmonary bacterial infections. These DDS are devoted to the delivery of clinically relevant 
antibiotics for inhalation, including tobramycin, colistin and ciprofloxacin, as well as 
exploited the simultaneous co-delivery of diverse anti-infectives. It is hypothesized that 
such DDS would address the significant problems in utilization of the aforementioned 
drugs, overcome biological barriers and improve drug bioavailability at the infection site. 
Moreover, the DDS would also allow the simultaneous delivery of antibiotic and quorum 
sensing inhibitor as a complementary therapy against bacterial biofilm infection. Hence, 
the antimicrobial efficacy of the antibiotics could be enhanced, eventually allowing to 
reduce the dosage of the used antibiotics and avoiding the development of bacterial 
resistance. 
To achieve those goals, this thesis aimed to design and synthesize the DDS which 
hold an optimized balance between the ability to overcome biological barriers and the drug 
loading capacity. This thesis also aimed to propose facile strategies for the synthesis and 
preparation of such DDS, which are suitable for large scale production and more relevant 
for the future potential clinical studies. Additionally, materials structural design and 
synthesis (e.g. degree of oxidation in starch, length of hydrophobic moiety and degree of 
hydrophobic substitution in amphiphilic chitosan derivative, the amphiphilicity of squalenyl 
derivatives) and conventional chemistry were carefully employed in tuning the DDS 
characteristics, maximizing the drug loading capacity, and controlling the drug release 
profile. 
 In the first part of the thesis, the simple polysaccharides-based polyplexes 
technology was reinterpreted which aimed to produce versatile DDS holding high drug 
loading capacity. In the subsequent studies, the novel farnesylated chitosan derivative, 
and amphiphilic squalenyl derivatives were designed and synthesized, with which I aimed 
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to prepare DDS based on self-assembling technology. Such DDS were hypothesized 
having core-shell structure, which was aimed to host a diversity of actives without 
scarifying the colloidal stability and characteristics. The drug loading capacity of such DDS 
would be improved compared to that could be achieved by using the polyplexes technique. 
This hypothesis was proposed to potentially reduce the use of the excipients in DDS, while 
the drug bioavailability would be maximized in the targeted site. Hence, the novel self-
assembled systems would be nominated as the versatile platforms for drug delivery. 
Notably, I aimed to go beyond the current state-of-the-art to design and synthesize the 
nano-assemblies of aminoglycoside antibiotics and farnesyl quorum sensing inhibitors as 
a dual-functional DDS that would completely avoid the use of any additional excipients. 
Such innovative DDS would thus reach 100% drug loading capacity, while its 
characteristics, in particular the size, are optimized to overcome the biological barriers. 
 Finally, this thesis further investigated the interaction between DDS and biological 
barriers, such as macrophages, mucus, and biofilm to be able to evaluate the advantages 
as well as the limitations of proposed strategies for anti-infective delivery.  
In this context, the major steps to achieve the aims are followed: 
(i) Structural design, synthesis and characterization of novel pharmaceutical 
excipients: the biocompatible and biodegradable materials based on carbohydrate 
polymers (starch, cyclodextrin, and chitosan derivatives), and natural lipids 
(terpenyl derivatives: squalenyl derivatives, and farnesyl derivatives) were 
employed in this work. The structure of the synthetic/modified excipients was 
designed to produce stable and uniform DDS, and to maximize the future loading 
of anti-infectives. 
(ii) Optimizing the preparation of delivery systems based on different techniques  
• Facile polyplex technology  
• Self-assembling technology 
ü Amphiphilic polymer-based nano-assemblies  
ü Amphiphilic lipid derivatives-based nano-assemblies 
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ü Innovative excipient-free nano-assemblies  
(iii) Optimizing the loading of clinically relevant antibiotics (tobramycin, colistin, 
ciprofloxacin), and a novel anti-infective QSI, as well as the co-loading of an 
antibiotic and a QSI as a complementary therapeutic formulation. 
(iv) Characterization and in-vitro safety studies of the novel DDS. 
(v) Investigation of the interaction between DDS and some important pulmonary 
biological barriers, such as macrophages, mucus/mucin and biofilm. 
(vi) Investigation of the efficacy of drug-loaded and drugs co-loaded delivery systems 
against bacterial biofilm infection. 
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3. MAIN FINDINGS 
In this thesis, the main findings section presents the significant results from three 
peer reviewed publications, a manuscript still in preparation for submission, and an 
international patent application. A summary about all the research discussed in this thesis 
will be in the following text, while detailed information of each publication and the summary 
of the invention will be presented in the scientific output, section 6. 
The first two publications present researches which aim to develop versatile drug 
delivery systems for pulmonary anti-infectives delivery based on biodegradable 
polysaccharides (starch, ß-cyclodextrin (ß-CD) and chitosan) using a facile method. The 
systems could encapsulate a variety of clinically relevant anti-infectives including highly 
water-soluble aminoglycosides, antimicrobial peptide, or poorly water-soluble quinolone. 
The materials used in these researches are biodegradable and biocompatible for 
nanomedicine applications, they are moreover suitable for large scale production as its 
environmentally friendly properties, and adaption to facile production procedures. 
However, the carrier systems produced from such natural polymers still confront some 
limitations including (i) in the controls of NPs characteristics and their physicochemical 
stability; and (ii) the reproducibility. These two issues are usually accounted for the 
heterogeneous properties of natural polymers, especially the molecular weight which is 
somehow not consistent in different batches; (iii) the lack of advanced multiple 
functionalization of the NPs due to the poor selectivity for further physical and chemical 
modification on particles surface (144). In these two chapters, the preparation of the 
anionic starch and anionic ß-cyclodextrin was revisited to have better control in molecular 
weight and degree of oxidation of resulting products. The products were then used for the 
complexation with chitosan derivatives to assemble NPs. The NPs characteristics (size 
and ζ-potential) could be easily tuned to befit the future application as drug delivery 
systems. Notably, the NPs size was ranged from 150 – 900nm. The system based on 
starch-chitosan polyplexes exhibited good drug loading capacity for hydrophilic 
tobramycin and colistin. The highest loading capacity of colistin in such simple system 
was nearly 23%. The ß-cyclodextrin-chitosan polyplexes significantly improved water-
solubility and shown controlled release profile of ciprofloxacin with the drug loading 
MAIN	FINDINGS	
	
	
37	
	
capacity ~10%. The NPs systems proposed in these two chapter are stable in biologically 
relevant medium and non-toxic (up to 1 mg/mL concentration) on human cell lines. The 
encapsulation of antibiotic into the complexation of these polysaccharides did not 
compromise the intrinsic antimicrobial efficacy of either compound. In the subsequent 
study, the dependence of NPs size on macrophage binding and uptake was investigated 
for the ß-cyclodextrin-chitosan particles having sizes ranged from 400 – 900nm. The 
overall research scheme carried in these chapters is depicted in Figure 8, and the detailed 
information of each research is presented in section 6.1 and 6.2, respectively. 
 
Figure 8. Overall research scheme discussed in section 6.1 and 6.2. 
In the next publication, the preparation of self-assembled nanocarriers based on a 
novel synthetic amphiphilic chitosan derivative, farnesylated glycol chitosan, is proposed. 
Having discussed that the majority of currently available, developed and discovered 
antimicrobial agents suffer from poor drug bioavailability due to their (i) poorly water-
solubility; (ii) short in vivo half-life in biological environment; and the potential adverse 
effects (86,145,146). Moreover, the co-delivery of diverse bioactive compounds is 
essential to enhance the therapeutic effects, in particular against bacterial infection (80). 
In chapter 6.3, in addition to the promising biocompatibility and biodegradability of the 
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used excipients, the core-shell structure of the assembled NPs is moreover expected to 
capable of carrying both hydrophilic and hydrophobic molecules which is the major 
limitation in loading capacity of the delivery systems composed by polysaccharides 
polyplexes. I proposed in this chapter a facile and high isolated yield method with one-
step synthetic reaction to prepare the farnesylated glycol chitosan. The uniform and stable 
NPs would be self-assembled in aqueous media at the relatively low degree of 
farnesylation (~11%), and was tuned in the size range of 200 – 500nm. The NPs drug 
loading capacity was investigated with different model compounds. And we convincingly 
proved the co-loading of both hydrophobic Nile red and hydrophilic fluorescent albumin 
protein in such NPs by CLSM, with reasonable drug loading capacity. Furthermore, the 
NPs exhibited excellent physiochemical stability in a wide range of biological relevant pH 
environment. Finally, the potential use of such nanoassemblies as mucosal drug delivery 
systems was investigated by studying the interaction between mucus-particle. An overall 
research scheme carried in this chapter is briefly summarized in Figure 9, and the detailed 
information of this chapter is presented in section 6.3. 
 
Figure 9. Overall research scheme discussed in section 6.3. Reprinted with permission 
from Reference (142) 
The subsequent chapter is presented in section 6.4, Squalenyl Hydrogen Sulfate 
NPs (SqNPs) for simultaneous delivery of tobramycin and alkylquinolone quorum sensing 
inhibitor to combat PA biofilm infections. This chapter pays more attention to the limitation 
of anti-infective penetration through bacterial biofilm, and bacterial communication via 
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quorum sensing systems which are suggested contributing to the fast resistance of PA 
biofilm infections. Furthermore, the influence of mucus/mucin on pyocyanin production 
level from PA was studied. Because such a layer is always present in the airway adding 
more challenge to the treatment of such infectious diseases (80). While drug-loaded 
nanocarrier is a promising strategy enhancing local drug delivery by crossing bio-barriers, 
a complementary to antibiotics, quorum sensing inhibitors (QSI), has been discovered 
capable to interfere with the biofilm formation (74,80). The dual-delivery of antibiotic and 
QSI is hypothesized to improve biofilm eradicating efficacy (73). Taking advantage of the 
self-assembling property of the newly synthesized anionic amphiphilic lipid, Squalenyl 
Hydrogen Sulfate (Sq), this chapter describes a dual-delivery nanocarrier with high 
loading capacity for both a lipophilic QSI (~10%) and the hydrophilic antibiotic tobramycin 
(~33%). The co-loaded system is expected to show actions on different stages of PA 
infection. Especially, the influence of mucus and mucin on the production of pyocyanin 
level from PA, as well as the function of QSI both in free form and loaded-SqNPs were 
also carefully investigated and reported. The novel platform in this study shows a 
significant therapeutic effect on eradicating PA biofilm infection. The tobramycin 
concentration used for a complete biofilm eradication is around 12.5 µg/mL when using 
dual-loaded carrier systems, while more than 200 µg/mL tobramycin alone is needed to 
show the same efficacy. Furthermore, the transport of the carrier system through biofilm 
was studied by live CLSM to clearly prove the improvement of therapeutic effect against 
PA biofilm infection. Figure 10 summarizes the hypothesis and research strategies in 
section 6.4.  
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Figure 10. Overall research scheme discussed in section 6.4. 
Finally, the last chapter, summarized in section 6.5, presents an innovative 
excipient-free nano-assemblies of aminoglycoside antibiotic and farnesyl quorum sensing 
inhibitors for combatting bacterial biofilm infections. The present invention relates to 
conjugates of aminoglycosides and terpenoids, in particular, sesquiterpenoids. 
Furthermore, the present invention relates to nano-assemblies formed by the inventive 
conjugates and to a method for producing the conjugates and/or the nano-assemblies. 
The present invention also relates to the inventive conjugates and nano-assemblies for 
use in therapy, in particular for use in the treatment of infectious diseases. Particularly 
preferred embodiments of the present invention relate to farnesylated aminoglycosides 
and nano-assemblies thereof, in which farnesol and its derivatives do not only function as 
a carrier for the aminoglycosides but do themselves have pharmaceutical activity upon 
cleavage of the conjugate, in particular quorum sensing inhibitory activity. Such nano-
assemblies of tobramycin and farnesyl quorum sensing inhibitor significantly enhance the 
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Pseudomonas aeruginosa biofilm eradicating efficacy 16-folds compared to the treatment 
of free tobramycin. 
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4. CONCLUSIONS AND OUTLOOK 
This thesis proposes different innovative strategies and platforms for the improved 
delivery of anti-infectives, especially for the treatment of pulmonary infections. The 
described delivery systems are biocompatible and biodegradable, and are manufactured 
using facile operations. They are stable in biologically relevant media and their 
physiochemical properties can be designed to fit the intended use. Materials structure 
design and conventional chemistry were successfully employed to explore and maximize 
the drug loading capacity and the potential of co-loading diverse agents in all studies with 
the aim to combat bacterial infection and to prevent the development of bacterial 
resistance. The efficacy against bacterial infection at different stages was evaluated in 
different biologically relevant environments (e.g. presence/absence of mucus or biofilm). 
Moreover, studying the interaction of these carrier systems with biological barriers, such 
as biofilm, mucus, and macrophages, allows to design and to prepare the drug delivery 
systems to overcome these barriers as needed for future therapeutic applications. 
In the first two chapters, section 6.1 and 6.2, the results clearly demonstrate that 
by overcoming the shortages of natural polymers properties, stable NPs could be formed 
by anionic polysaccharides based on starch or ß-cyclodextrin polyplexes with chitosan 
derivatives using a facile method. The technique allows to flexibly tune size and surface 
characteristics, and the encapsulation of various types of anti-infectives without 
compromising their anti-microbial function. In addition, the size dependence of 
macrophage uptake recommended the use of the sub-micro carriers for the treatment of 
extracellular infections. Moreover, the research in these chapters also show the potential 
of flexible surface modification of those carriers with hydrophilic enzymes or nucleases 
(e.g. deoxyribonuclease I) to enhance drug penetration through biofilm or mucus. This 
approach has good prospects for developing inhalation nanomedicines against pulmonary 
infections. 
In the next chapter, section 6.3, the natural polymer chitosan was chemically 
modified by coupling to a hydrophobic farnesyl moieties resulting in a novel amphiphilic 
polymer. The latter shown an interesting self-assembling to core-shell particles, capable 
to overcome the limitation of natural polysaccharides carrier systems in various ways: (i) 
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allowing the encapsulation of the hydrophobic compounds, (ii) enabling the simultaneous 
delivery of a second active with different structure and physiochemical properties, (iii) and 
allowing the further surface modification to render the system more flexible to various 
applications. In this chapter, the interaction of the particles with mucus as a biological 
barrier was explored in more detail, and the novel system appeared as a versatile DDS 
for various mucosal routes of application. 
The last two chapters describe two novel carrier systems, capable to 
simultaneously deliver antibiotics and QSI molecules as high efficiency and loading 
capacity. The first system was formed by the simultaneous self-assembly of squalenyl 
hydrogen sulfate, aminoglycoside antibiotics, and QSI molecules. The second system is 
the excipient-free nano-assembly of an aminoglycoside (tobramycin) and farnesyl QSI. In 
study the efficacy against PA infection, it was surprisingly found that the presence of 
mucin/mucus increased the production of the virulence factor pyocyanin. Both DDS 
systems shown impressive effects against biofilm forming PA bacteria, indicating a 
remarkable improvement in bioavailability of both active compounds at the site of infection 
and in particular inside the biofilm, which was also supported by CLSM images. Based on 
these promising results in vitro, in vivo studies on infection relevant models are currently 
ongoing.  
Altogether, this thesis describes some novel strategies for anti-infective delivery 
systems, their advantages and limitations, and the understanding gained from 
investigating the interaction of such systems with various biological barriers. The author 
is convinced that these data will provide valuable information for the comprehensive 
investigation and development of novel therapeutic modalities to better combat bacterial 
infections in the future. 
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6.1. PAPER 1: “Starch-Chitosan Polyplexes: A Versatile Carrier System for Anti-
Infectives and Gene Delivery” 
 
 
This chapter is the following publication: 
 
Starch-Chitosan Polyplexes: A Versatile Carrier System for Anti-Infectives and 
Gene Delivery 
 
Hanzey Yasar*, Duy-Khiet Ho*, Chiara De Rossi, Jennifer Herrmann, Sarah Gordon, 
Brigitta Loretz and Claus-Michael Lehr; Polymers. 2018, 10, 252. 
 
* These authors contributed equally to this work. 
DOI: 10.3390 / polym10030252 
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6.2. PAPER 2: “Polysaccharide Submicrocarrier for Improved Pulmonary 
Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, 
Characterization, and Influence of Size on Cellular Uptake” 
 
This chapter is the following publication: 
 
Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly 
Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence 
of Size on Cellular Uptake 
 
Duy-Khiet Ho, Ana Costa, Chiara De Rossi, Cristiane de Souza Carvalho-Wodarz, 
Brigitta Loretz, and Claus-Michael Lehr; Mol. Pharmaceutics. 2018, 15, 1081-1096 
DOI: 10.1021/acs.molpharmaceut.7b00967 
 
 
 
 
 
 
 
Reprinted from Molecular Pharmaceutics, Polysaccharide Submicrocarrier for Improved 
Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, 
Characterization, and Influence of Size on Cellular Uptake; Duy-Khiet Ho, Ana Costa, 
Chiara De Rossi, Cristiane de Souza Carvalho-Wodarz, Brigitta Loretz, and Claus-
Michael Lehr; 2018, 15, 1081-1096 Copyright (2018) American Chemical Society, 
published by Copyright Clearance Center, Inc., with permission from American Chemical 
Society. 
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6.3. PAPER 3: “Farnesylated Glycol Chitosan as a Platform for Drug Delivery: 
Synthesis, Characterization, and Investigation of Mucus−Particle Interactions” 
 
This chapter is the following publication: 
 
Farnesylated Glycol Chitosan as a Platform for Drug Delivery: Synthesis, 
Characterization, and Investigation of Mucus−Particle Interactions 
 
Duy-Khiet Ho, Sarah Frisch, Alexander Biehl, Emmanuel Terriac, Chiara De Rossi, 
Konrad Schwarzkopf,	 Franziska Lautenschläger, Brigitta Loretz, Xabier Murgia, and 
Claus-Michael Lehr; Biomacromolecules. 2018, 19, 3489-3501. 
DOI: 10.1021/acs.biomac.8b00795 
 
 
 
 
 
 
 
Reprinted from Biomacromolecules, Farnesylated Glycol Chitosan as a Platform for Drug 
Delivery: Synthesis, Characterization, and Investigation of Mucus−Particle Interactions; 
Duy-Khiet Ho, Sarah Frisch, Alexander Biehl, Emmanuel Terriac, Chiara De Rossi, 
Konrad Schwarzkopf, Franziska Lautenschläger, Brigitta Loretz, Xabier Murgia, and 
Claus-Michael Lehr; 2018 Copyright (2018) American Chemical Society, published by 
Copyright Clearance Center, Inc., with permission from American Chemical Society. 
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6.4. PAPER 4: “Squalenyl Hydrogen Sulfate nanoparticles for simultaneous 
delivery of tobramycin and alkylquinolone quorum sensing inhibitor to combat 
P. aeruginosa biofilm infections” 
The data presented in this chapter are subjects of a forthcoming manuscript, 
authored by Duy-Khiet Ho, Anastasia Andreas, Xabier Murgia, Antonio G. Hüfner de Mello 
Martins, Chiara De Rossi, Marcus Koch, Jennifer Herrmann, Rolf Müller, Martin Empting, 
Rolf W. Hartmann, Didier Desmaele, Brigitta Loretz, Patrick Couvreur and Claus-Michael 
Lehr. 
Squalenoylation is a unique technology allowing spontaneously self-assembly of 
drug bioconjugated with just one squalenyl moiety, which at the same time results in a 
significant high loading capacity, usually higher than 30%, mostly depending on the 
molecular weight of drug molecule (1). This innovative approach has been widely applied 
for anticancer drugs, e.g. gemcitabine and doxorubicin, as well as antibiotics, e.g. 
penicillin G, and shown considerable improvement in efficacy against cancer and 
intracellular infection (2,3). The technique is, however not successfully employed for other 
drug molecules having abundant amount and different functional groups, e.g. 
aminoglycosides antibiotics. Moreover, the overall concept of the squalenoylation is to 
synthesize the amphiphilic structure of the conjugated drugs which would further 
assemble into a particulate formulation. The solubility of the resulting compounds thus 
becomes a severe limitation, especially in common solvents, for the nano-precipitation 
procedure (4). Consequently, despite the usefulness of such innovative technology, their 
use has not yet been completely explored. To take advantages of the squalenoylation 
technology and to further exploit the drug loading capacity of systems based-squalenyl 
derivatives, I propose here a newly synthesized amphiphilic anionic lipid, squalenyl 
hydrogen sulfate, which could easily assemble into nano-sized particles in aqueous 
solution. The self-assembling property of the new compound is much stronger compared 
to the carboxylic squalenyl derivative due to the high polarity of the hydrogen sulfate 
functional group. The compound was moreover synthesized and isolated with a high yield, 
and the synthetic procedure is promising for a large scale production. The synthetic 
scheme and isolated yield of each step are shown in Figure 1A. 
SCIENTIFIC	OUTPUT	
	
112	
	
 
 
Figure 1. (A) Synthetic scheme of Squalenyl Hydrogen Sulfate (Sq) and the assemblies of Sq into drug-
free SqNPs, QSI (1)-loaded SqNPs, Tob-loaded SqNPs and Tob & (1) co-loaded SqNPs; the attached table 
(a1-a4) indicate the NPs characteristics, encapsulation efficacy (EE%) and loading capacity (LC%). (B) 
Cryo-TEM image of Tob & (1) co-loaded SqNPs. (C) Cumulative release of Tob and QSI (1) in PBS, at 37 
°C. All data are presented as mean ±SD, at least three independent experiments performed in triplicate 
each. 
  
Self-assemble in aqueous solution
Aqueous solution
Aqueous solution
Aqueous solution
Co-assembly with Tobramycin and QSI (1)
Drug free-SqNPs
(1)-loaded SqNPs
Tob-loaded SqNPs
Tob & (1) co-loaded SqNPs
Size (nm) 192.0±1.1
PDI 0.10±0.02
ζ-potential (mV) 6.8±1.3
Size (nm) 194.9±2.0
PDI 0.08±0.02
ζ-potential (mV) 12.6±0.3
EE (%) 90.7±5.2
LC (%) 29.8±3.4
Size (nm) 166.7.0±1.5
PDI 0.09±0.01
ζ-potential (mV) -44.8 ± 1.3
Size (nm) 172.6±1.3
PDI 0.10±0.01
ζ-potential (mV) -38.1±2.09
EE (%) 95.1±0.8
LC (%) 9.3±0.3
A)
B) C)
a1)
a2)
a3)
a4)
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The obtained drug-free self-assembled NPs were stable in storage conditions (4 
ºC) and in biologically relevant medium for more than a month (data not shown), and 
biocompatible on human cell line A549. The single drug-loaded SqNPs, and drugs co-
loaded SqNPs were simply obtained by co-precipitation of the drug molecules and Sq in 
aqueous media. The procedures are depicted in Figure 1A. Impressively, the drug loading 
capacity of the system is remarkably higher than the conventional drug delivery systems 
reported in previous studies (5,6). Particularly, the loading capacity of Tob is at maximum 
30%, and the highest loading capacity of QSI (1) is at nearly 10% which are notably higher 
than the 0.05% loading capacity reported by Nafee et. al. (7). The NPs characteristics are 
summarized in table (a1-a4) attached in Figure 1A. Morphology of such co-loaded SqNPs 
was observed by Cryo-TEM and presented in Figure 1B. 
The release study of Tob and QSI (1) co-loaded SqNPs was performed in PBS at 
37 ºC, and the results are depicted in Figure 1C. It is undoubted that the hydrophobic QSI 
(1) shown a slower release profile as the molecules localized in the core side of NPs, while 
tobramycin was released faster when being decorated on the outer part of the systems. 
The release of tobramycin shown burst effect at around 30% which was recorded after 4h 
incubation. This result proves the strong electrostatic interaction between amine and 
hydrogen sulfate functional groups in tobramycin and Sq, which is an advantage over the 
liposomal tobramycin formulation. In addition, the system holds the potential of co-loading 
high amount of different active compounds, which is a remarkable improvement in 
comparison to existing nano-formulation systems.   
Experts voice that the cell density-dependent cell-to-cell communication system 
used by PA strains which is referred to as quorum sensing system is for coordinating 
group behavior such as the production of virulence factors such as pyocyanin, elastase B 
and hydrogen cyanide (8,9). As a result, the biofilm formation is occurred to protect 
bacteria from environmental stresses and promoted the resistance development. Within 
the PA signal quorum sensing system, PqsR (pseudomonas quinolone signal R) is a vital 
DNA-binding receptor, which in particular means the system is specific to PA and a critical 
regulator that fine-tunes a set of genes encoding for virulence factors (10–13). Pyocyanin 
is, in part a generator of reactive oxygen species superoxide and hydrogen peroxide which 
benefit the bacterial colonization by damaging a variety of host cells and inhibiting the 
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dual-oxidase based antimicrobial system in the respiratory regions (14,15). Moreover, the 
pseudomonas quinolone signal also prompts PA to convert to a metabolically less active 
state in which bacteria are not sensitive to antibiotics. As pseudomonas quinolone signal 
shows a prominent role in PA biofilm formation, development and resistance, it is thus 
considered an attractive target for combatting bacterial resistance (16). A highly affine 
PqsR antagonist, QSI (1) (the structure is shown in Figure 1A), was discovered and 
synthesize for such purpose. This QSI was determined to strongly inhibit the virulence 
pyocyanin of PA wt, which as a consequence influences the formation of biofilm (17). The 
therapeutic effect of such potent compound is restricted by its poor water-solubility. 
Hence, a drug delivery system would be a solution to improve the availability of the QSI 
(1) in aqueous solution. Figure 2 compares the production of pyocyanin level (%) after 
incubating PA14 wt strain with either free QSI (1) or the QSI (1)-loaded SqNPs at different 
concentrations. As can be seen, the effectiveness in inhibiting pyocyanin production was 
improved more than three times by loading the compound to SqNPs. This proves the 
importance of drug availability enhancement in an aqueous-like environment. 
 
Figure 2. Pyocyanin assay performed on PA14 wt; starting OD600 (0.02), incubation time 16h. The EC50 
values of each treatment was calculated by fitting sigmodal curve, OriginPro 2018 (OriginLab Corp., USA). 
Significant different shows at level *p<0.001 compared with sample treated with 0.5 µM QSI (1), #p<0.001 
compared with sample treated with 20 µM; §p<0.001 compared with sample treated with 8µM; &p<0.001 
compared with sample treated with 4µM. The production of pyocyanin level of PA14 wt, and PA14 wt 
incubated with drug-free SqNPs were also measured and served as controls. The drug-free SqNPs did not 
show any inhibition to pyocyanin production on PA14 wt at the tested concentrations. PA14 wt bacteria were 
grown in PPGAS (proteose peptone glucose ammonium salt medium which is composed of (1 g/L NH4Cl, 
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1.5 g/L KCl, 19 g/L Tris-HCl, 10 g/L peptone, glucose 5 g/L and 0.1 g/L MgSO4•7H2O), the medium was 
adjusted to pH 7.4, and sterilized before use). All data are presented as mean ±SD, at least three 
independent experiments performed in triplicate each. 
The mucus layer presents in the airway is always the first contact of bacteria once 
they start colonizing and infecting the host. The pulmonary mucosal barrier would of 
course be a protecting layer to prevent the first state in colonization of pathogens, clinical 
studies have however revealed that such barrier becomes a superior environment for 
bacterial resistance development, in particular PA associated infections in cystic fibrosis 
patients (18). Hence, I investigated the pyocyanin production level of PA14 wt strain in the 
presence of mucin, a main component of mucus, and native human tracheal mucus at 
different concentrations. The results are shown in Figure 3 (A-B). Interestingly, our study 
pointed out that at the highest tested concentrations of mucin and mucus, pyocyanin 
production in PA14 wt was inhibited which importantly proves the natural defending 
function of mucus layer which is in addition to the size- and charge-filtering and 
mechanisms. On the contrary, when decreasing the concentration of mucin and mucus 
which meaning increasing the ratio of bacteria availability to mucin and mucus weight, the 
pyocyanin production was not inhibited but even enhanced significantly, in particular when 
incubating PA14 wt with mucin 0.25% or mucus 0.05% concentration, the results are 
depicted in Figure 3 (A-B). 
QSI is aimed to inhibit pyocyanin production level, which as a consequence 
prevents the biofilm formation and rescues the utilities of antibiotics in the treatment of 
infections. As described in Figure 10 of the “Introduction” section, QSI should be active at 
all stages of infection so that antibiotic therapeutic efficacy would be enhanced, and biofilm 
would possibly be eradicated completely. Although both free QSI (1) and QSI (1)-loaded 
SqNPs performed their pyocyanin inhibiting functions, the presence of mucus or mucin at 
which concentrations favor the production of pyocyanin would reduce and even inactivate 
the action of QSI in either form. The pyocyanin assay was carried out to check this 
hypothesis, all PA14 wt samples grown in either bacterial culture medium (PPGAS), 0.1% 
mucin in PPGAS, or 0.025% mucus in PPGAS were treated with either 2 µM QSI (1) as 
free form or loaded in SqNPs. In all these media, the PA14 wt bacteria were also grown 
without treatment and served as controls. The results are summarized and presented in 
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Figure 3C. Our hypothesis holds true in cases using free form QSI (1) for treatment, its 
inhibiting actions were decreased and even not functioned in present of 0.025% mucus 
and 0.1% mucin, respectively. On the contrary, QSI (1)-loaded SqNPs still shown the 
similar effects compared to ones observed in the assays performed in the absence of 
mucus or mucin. Furthermore, at a significantly lower concentration of mucus, the 
performance of free form QSI was not notably reduced. Thus, the remarkable reduction 
in therapeutic efficacy observed when applying QSI (1) in the presence of mucin would 
be explained by the limitation in solubility of the QSI (1) molecules. The argument is quite 
understandable due to the rather viscous solution resulting from dissolving mucin in 
PPGAS solution. Moreover, the glycoprotein mucin has heterogeneous properties and 
holds hydrophobic regions in its structure which would adsorb QSI (1) molecules upon 
contacting in aqueous solution thank to the hydrophobic interaction. Therefore, such QSI 
molecules are not well dispersed and available to inhibit the production of pyocyanin. On 
the other hand, the QSI-loaded SqNPs would have a better dispersion in the medium and 
show relatively consistent efficacy of inhibition. 
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Figure 3. Pyocyanin assay 
A) The production of pyocyanin levels in present of mucin compared to the control PQ14 wt grown in PPGAS 
culture medium. Significant level show at *p<0.001 compared with controls; #p<0.001 compared with 
samples incubated with mucin 1%; &p<0.001 compared to samples incubated with mucin 0.25%; §p<0.001 
compared to samples incubated with mucin 0.1%. B) The production of pyocyanin levels in present of mucus 
compared to the control PQ14 wt grown in PPGAS culture medium. Significant level show at *p<0.001 
compared to controls; #p<0.001 compared to samples incubated with mucus 0.5%; §p<0.001 compared to 
samples incubated with mucus 0.1%. C) Comparison of pyocyanin production level in PA14 wt samples 
grown in either bacterial culture medium (PPGAS), 0.1% mucin in PPGAS, or 0.025% mucus in PPGAS 
were treated with either 2 µM QSI (1) as free form or loaded in SqNPs. *p<0.001. All data are presented as 
mean ±SD, at least three independent experiments performed in triplicate each.  
As shown in Figure 4A, once bacteria are protected in biofilm, the concentration of 
tobramycin needed to completely eradicate bacterial infection was 200 µg/mL or higher 
which is remarkably higher than that needed to against planktonic PA14 wt. The fact of 
A) B)
C)
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higher Tobramycin dose needed to eliminate biofilm is known and was verified here. The 
need of a higher dose is a challenge in biofilm-associated infections, especially that could 
promote bacterial antibiotic resistance development. The tob-loaded SqNPs holding 
controlled release profile of tobramycin shows a slight improvement with an identified 
MBEC value at 200 µg/mL. The free-form mixture of tobramycin and QSI (1) in which QSI 
(1) concentration was kept constantly at 20 µM performed better in combatting PA14 wt 
biofilm compared to the aforementioned treatments. In addition to the decreasing of MBEC 
value of tobramycin down to 100 µg/mL, the overall bacteria availability in all tobramycin 
treating concentrations was reduced compared to those treated without QSI (1). The 
results show encouraging therapeutic effect of the antibiotic and QSI combination. One 
might hypothesize that QSI would inhibit the production of pyocyanin and prevent the 
further development of the already established biofilm, which thus causes a weaker biofilm 
structure and increase the sensitivity of bacteria to antibiotic. Moreover, the less formation 
of biofilm would further limit the transformation of bacteria to persister stage, which would 
restrict the resistance development. Having known that QSI (1)-loaded SqNPs would 
enhance the inhibiting functions of QSI (1), we further applied the tob & QSI (1)-co-loaded 
SqNPs in MBEC assay, in which QSI (1) concentration was also incubated continuously 
at 20 µM. The results are shown in Figure 4D. Interestingly, tobramycin needed for the 
complete biofilm eradication was significantly reduced and reached around 12.5 µg/mL 
which is nearly 16-fold lower than that of free tobramycin. The interestingly remarkable 
enhancement would be the results of better bioavailability of QSI (1) through the biofilm 
due to the good dispersion and transportation of such hydrophobic drug loaded in SqNPs, 
which was further confirm by CLSM images shown in Figure 5. In summary, the results of 
the MBEC assay show that the novel drugs co-loaded SqNPs have a remarkable 
complementary therapeutic effect that befit the biofilm eradicating properties and are 
superior to free tobramycin. The proposed platform and gained knowledge in this research 
would definitely devote to the further studies in combatting bacterial biofilm resistance 
development. 
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Figure 4. Minimum Biofilm Eradicating Concentration Assay. 
PA14 wt biofilm grown in PPGAS for 24h (starting OD600=3.0) were treated with A) Tobramycin (Tob); B) 
Tob-loaded SqNPs; C) both Tob and QSI (1) as free form; D) Tob and (1) co-loaded SqNPs. The 
concentration of QSI (1) was kept constant at 20 µM in all experiments. After 24h incubation, efficacy was 
assessed by determination of cfu/mL. Cfu/mL values are depicted logarithmically for n = 3 experiments with 
technical triplicates each. PA14 wt biofilm, and PA14 wt biofilm treated either with drug-free SqNPs, or with 
QSI (1), or QSI (1)-loaded SqNPs were served as controls. The dotted line indicates the detection limit. 
Significant different shown at level *p<0.001 compared to controls; #p<0.001 compared to samples treated 
with Tob 3.125 µg/mL; §p<0.001 compared to samples treated with Tob 6.25 µg/mL; and &p<0.001 
compared to samples treated with Tob 12.5 µg/mL. 
A) Free Tob B) Tob-loaded SqNPs
C) Tob & (1)
CM (1) was kept constant at 20 µM
D) Tob & (1) co-loaded SqNPs
CM (1) was kept constant at 20 µM
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Figure 5. CLSM study of Tob & Nile-red-co-loaded SqNPs 190 nm (Tob concentration was 25 µg/mL which 
is below the MBEC value of Tob-loaded SqNPs) interaction and transport through PA GFP 24h-old biofilm 
(starting OD600=3.0) after 4h incubation (PA GFP: Pseudomonas aeruginosa green fluorescent protein in 
Green, Nile-red loaded SqNPs in red). The images show the bottom layer of the PA biofilm in which SqNPs 
are found proving for the penetration of such system through the biofilm. 
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6.5. PATENT APPLICATION: “Excipient-free nano-assemblies of aminoglycoside 
antibiotics and farnesyl quorum sensing inhibitors for combatting bacterial 
biofilm infections” 
 
This chapter is the following filed patent application: 
 
Duy-Khiet Ho, Brigitta Loretz, Claus-Michael Lehr; Aminoglycoside derivatives and nano-
assemblies thereof, including those with quorum sensing inhibitory function. 
 
European Patent Application, EP 17 179 011.6 
International Patent Application, PCT/EP2018/065232 
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6.5.1. Proof of European Patent Application 
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6.5.2. Proof of International Patent Application 
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6.5.3. Summary of the invention 
In this section, the description of state-of-the-art and some results in the invention 
will be summarized and presented. The invention will be published online from January 
2019. 
Aminoglycosides is an important antibiotic family which is widely used in clinical to 
treat many infectious diseases, especially for many types of gram-negative bacteria and 
biofilm. Tobramycin, for instant, is widely used for several infectious diseases with different 
formulating strategies, e.g. i) TOBI® solution for inhalation (product of Novartis) is a 
tobramycin solution for inhalation for lung infection, particularly in cystic fibrosis patients. 
This product is recommended to use as 300mg tobramycin in 5 mL ampule for a single 
use for 28 days. ii) TOBI® PODHALER™ (product of Novartis) is tobramycin inhalation 
powder. This product is administered 28 mg capsules for inhalation twice-daily for 28 days 
(1–3). iii) Tobramycin Ophthalmic Solution, USP 0.3% (product of Bausch and Lomb) is 
tobramycin for ophthalmic infection (4). iv) and many other examples such as gentamicin 
and neomycin for infectious skin, amikacin for a wide range of multi-resistant bacteria.  
Although there are tremendous development in therapeutic approach, particularly 
new drug class synthesis, as well as formulating and administering strategies, the clinical 
treatments using aminoglycosides remain failures because: (i) The drugs could only 
accomplish the termination of spreading bacteria, while biofilms and mucus-embedded 
biofilms could impossibly be eradicated completely; (ii) The high dose of aminoglycosides, 
e.g. in case of TOBI® solution for inhalation, which is required for the treatment of cystic 
fibrosis related infection, causes side effects on patients when the drug is burstly released; 
(iii) The naturally highly charged structure of aminoglycosides would cause strong 
interaction with biological barriers, e.g. biofilm or mucus, leading to a slow or incomplete 
penetration of drug to infected side. As a result, aminoglycosides dose could be below 
MIC value which is a main cause of bacterial resistance.  
With mentioned reasons, the uses of aminoglycosides are necessary, but there are 
limitations that need to be solved. Although new analogs of aminoglycosides could be 
synthesized and introduced to expectedly improve antimicrobial properties, their highly 
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positive charged structure could potentially again be a problem causing resistance in 
bacteria due to its strong interaction with biological barriers, especially in complex 
infectious diseases. Hence, it is important to prepare new analogs of such antibiotic family, 
and to innovate a strategy to overcome biological barriers. Formulating and combining 
aminoglycosides with other active agents as the complementary treatment in the nano-
sized carriers would be a good problem solving approach. 
Nanotechnology in pharmaceutical applications has been evaluated as a high 
efficacy technique in the delivery of drugs, which aims to protect drugs from degradation 
and burst release, and to deliver a sustainable amount of drugs to targeting sites. 
Particularly considering novel strategies of drug delivery for infectious diseases treatment, 
nanotechnology is the most advantageous technique, which could locally delivery 
sufficient does of anti-infective, allows a combination of more than one active agent in 
targeting side to maximize treatment efficiency, and avoids drugs side effects as well as 
bacterial resistance development. Although there are many intense studies on developing 
nanomedicines for severely infectious diseases, it is obvious that few nanomedicine 
products have reached to clinical stage and market. Those failures are because of: (i) The 
poor loading rate with respect to carrier materials; (ii) The burst release of encapsulated 
drugs right after administration; (iii) It is hard to choose the materials which are 
biodegradable, biocompatible, and easy for the design of carrier systems that could 
overcome biological barriers; (iv) Lack of multifunctional nano-carrier systems, or 
limitation in multi-loading carrier system regarding loading capacity, types of loading 
agents, loading efficiency and loading rate.  
In this invention, we propose an innovative strategy which is ‘excipient free nano-
assembly of aminoglycosides and quorum sensing inhibitors’ by farnesylation of 
aminoglycosides molecules. Farnesol is a natural and biocompatible lipid (C15H26O) 
belonging to the sesquiterpene alcohols, which is widely employed in many medical 
products. “Farnesylation” means the covalently chemical linkage, or electrostatic 
interaction of farnesyl derivatives and drug molecules via a “single step” preparation which 
is proposed in this innovation. Without the need of any other supporting materials, the 
innovated technique allows spontaneous formation of aminoglycosides nanoparticles 
based on self-assembly of farnesol derivatives. Moreover, farnesol and its derivatives 
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have known pharmacological effects (5,6) which are: i) anti-biofilm activity (7); ii) bacteria 
(e.g. Pseudomomas aegurinosa) and fungi quorum sensing inhibitory properties, as well 
as improving treatment efficiency when co-administrating with antibiotic (8–10); iii) 
antibacterial and antifungal (5,11,12); and iv) induction of apoptosis in cancer cells 
(13,14). Those properties of farnesol derivatives, particularly quorum sensing inhibitory 
properties, would be greatly employed in this innovation. Therefore, in this innovation, the 
‘excipient free nano-assembly of Aminoglycosides and quorum sensing inhibitors’ by 
farnesylation is composed of antibiotic, aminoglycosides, and quorum sensing inhibitor 
derivatives, farnesol derivatives, which is considered 100% nano-assembly medicine for 
infectious diseases treatment. 
Such remarkable self-assembly properties were demonstrated before for squalene 
(C30H50; Mw = 410 g/mol) the precursor of steroids. Squalenoylation was shown to be a 
viable strategy for drug delivery (15). However, the Squalenoylation technology has 
unsolved disadvantages compared to the innovative ‘Aminoglycosides Nano-assembly’ 
by farnesylation, which are: (i) Squalene derivatives do not have quorum sensing inhibitory 
properties; hence, it is just a novel carrier system, or pro-drug form. Meanwhile, in this 
innovation, the ‘Aminoglycosides Nano-assembly’ is considered as 100% therapeutic 
nano-medicine (the excipient free nano-assembly) as it is composed by antibiotic, 
aminoglycosides, and quorum sensing inhibitory derivatives, farnesol derivatives; (ii) 
Preparation of squalene derivatives is multi-step synthesizing procedure (generally more 
than 5 steps) and poor isolated yield, especially around 30% isolated yield for 1st step of 
synthesis procedure, which results in low overall isolated yield (16,17); (iii) Conjugation of 
squalene derivatives to highly charged compounds causes serious solubility problem of 
resulting products, which is a huge limitation for nano-carriers preparation and application 
as reported by Lepeltier et. al. (18); (iv) Farnesol derivative is a precursor of squalene, so 
squalene derivatives have almost double molecular weight and are harder available and 
producible. The drugs loading rate of nano-carriers based on squalene derivatives would 
be definitely lower compared to farnesol derivatives considering same drug molecules. 
Besides, farnesol derivatives were previously used to modify with penicillin G 
(19,20); however, the aim of that research was completely different compared to the focus 
of this innovation, with reasons as following: (i) The research aimed to treat intracellular 
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infection, in eukaryotic cells, the non-biofilm infection. The function as quorum sensing 
inhibitor of farnesol derivatives was not employed and studied, and farnesol derivative in 
their research was just used as a carrier. While the aim of this innovation is 
‘Aminoglycosides Nano-assembly’ for dual delivery of aminoglycosides and quorum 
sensing inhibitor, the farnesol derivatives, for biofilm treatment. (ii) In the proposed 
research by Abed el. al. (20) non-cleavable (ester bonds) and intracellular cleavable 
linkage (acylal linkage) of farnesol derivatives and drug molecules were used resulting in 
non-active properties of farnesol for intracellular infection. While in this innovation the 
linkage of farnesol derivatives and aminoglycosides is designed and synthesized to be 
cleaved due to pH gradient of biofilm (e.g. imine, enamine) as environmentally sensitive 
linkage (the linkage in this innovation is not designed to be cleaved intra- eukaryotic cells), 
or is statistic interaction. Hence, quorum sensing inhibitory function of farnesol derivatives 
would be maintained in targeting sides (e.g. biofilm). Besides, the conjugation of farnesol 
derivatives and penicillin G by Abed et. al. (20) required spacing molecules (for better 
conjugation and control environmental sensitivity of linkage), while in this invention 
aminoglycosides and quorum sensing inhibitors, farnesol derivatives, were directly 
conjugated by pH-sensitive linkage. As a result, cleaved products of modified compounds 
in such approach are not quorum sensing inhibitors due to the presence of spacing 
molecules, while in this invention the conjugation without spacing molecules of the 
excipient free nanomedicine will directly release farnesol derivatives, which are quorum 
sensing inhibitors, and aminoglycoside molecules. (iii) The use of farnesol derivatives in 
their research did not help to improve antimicrobial activity of penicillin G as mentioned in 
Table 2 in their publication, and even dramatically decrease antimicrobial activity of 
penicillin G, or non-active compound after conjugation (by showing the remarkable 
increase of minimum inhibitory concentration (MIC) at more than 3250 folds higher 
compared to free drug. Note: the result in MIC assay shows that one of the modified drugs 
with farnesol derivative does not have antimicrobial activity). While in this innovation, the 
active sides of aminoglycosides (amine functional groups) are maintained in targeting 
sites as selectively cleavable linkage and/or statistic interaction of quorum sensing 
inhibitors, farnesol derivatives, and aminoglycosides are prepared. Moreover, the dual-
delivery of 100% therapeutic nanomedicine (the excipient free nano-assembly) shows 
great improvement in treatment efficiency as the function of two active agents, with 
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dramatically decreasing in MIC value. (iv) In their research, the ß-Lactam antibiotic family 
was studied, which is used in completely different aim from aminoglycosides antibiotic 
family, the focus in this innovation; hence, they have different problems considering their 
applications and development. And in this innovation, problems of aminoglycosides are 
carefully addressed. 
In addition, the introduction of lipophilic moieties into molecules of 
aminoglycosides; particularly modification of Tobramycin, or Kanamycin, were 
investigated in previous research proposed by Fosso et. al. (21) and Berkov-Zrihen et. al. 
(22). The aim in these researches was to use chemical modification to introduce lipophilic 
derivatives into aminoglycosides to make cationic amphiphiles which could promote better 
penetration of modified compound to bacteria cell walls, or vary the anti-microbial activity 
(which was studied by MIC assay). However, such modification in those studies could not 
bring great impact in infectious diseases treatment compared to the modification in this 
invention. The main disadvantages in those researches and the differences compared to 
this innovation are mentioned as below: (i) The lipophilic moieties which were used in 
those researches are linear hydrocarbon (from C4 to C15). Those hydrocarbon derivatives 
do not have self-assembly properties so that the formation into nano-sized carriers is not 
possible. While in this innovation the use of farnesol derivatives is for self-assembly of 
aminoglycosides into nano-sized carrier systems. (ii) The lipophilic moieties which were 
used in those researches do not have quorum sensing inhibitory properties. While the 
farnesol derivatives in our innovation are employed as quorum sensing inhibitors which 
are greatly employed for a formulation of 100% therapeutic nanomedicine (the excipient 
free nano-assembly). (iii) In those researches, lipophilic moieties were modified to 
aminoglycosides derivatives with stable linkage (non-cleavable linkage) toward 
aminoglycosides, which definitely changes properties of the active sites of 
aminoglycosides; therefore, the modified drugs could be considered as new compounds. 
Consequently, in most cases, the introduction of lipophilic moieties results in poor anti-
microbial activities. While in this innovation, the introduction of farnesol derivative does 
not compromise anti-microbial properties of aminoglycosides, but dramatically increases 
the treatment efficiency due to dual action of two active agents in 100% therapeutic 
nanomedicine (the excipient free nano-assembly). (iv) The introduction of lipophilic 
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moieties was done by heavily employing chemical synthesis, which is multi-step synthetic 
procedure (generally more than 7 steps) with poor isolated yield, and non-scalable 
strategy. While in this innovation we have developed the ‘single step’ preparation of 
aminoglycosides nano-assembly which incorporates more than one active compound for 
better treatment efficiency, and is a scalable procedure with 100% conversion yield and 
95% isolated yield. 
Finally, the incorporating administration of an antibiotic (ciprofloxacin) and quorum 
sensing inhibitor (farnesol) by formulating them into liposome vehicle to treat biofilm 
infections results in greater treatment efficiency compared to single administration of each 
free drug proposed by Bandara et. al. (10). However, i) the novel carrier, liposome, used 
in their research has poor loading rate due to its natural characteristic of such carrier 
system and the use of abundant amount of lipids to formulate liposome which are 
dominant compared to amount of loading drugs; and ii) there is no direct connection 
(linkage) between antibiotic molecules and quorum sensing inhibitors in their research, 
they were just applied as free form in the formulation; hence, the release of drugs were 
not well controlled; iii) Moreover, ciprofloxacin could easily form crystal in an aqueous 
medium in short time at storage conditions, so the use of ciprofloxacin in aqueous phase 
of liposome is not a good approach. Hence, the differences between this innovation and 
the work by Bandara et. al. (10) are: (i) In this innovation, the 100% therapeutic 
nanomedicine (the excipient free nano-assembly) without any supporting materials has 
been innovated which is a huge advantage compared to liposome carrier; (ii) moreover, 
the cleavable linkage or statistic interaction of farnesol derivatives and aminoglycosides 
is able to form stable nano-assembly to avoid burst release, and manage to have the 
release of drugs in a controlled manner. 
With all above mentioned reasons, this innovation proposes a completely different 
approach for nanomedicine formulation of aminoglycosides and farnesol derivatives.  
The concept of self-assembly antibiotic aminoglycosides and quorum sensing 
inhibitory farnesol derivatives into a nanomedicine system is unique, and a completely 
different focus on nanomedicine development compared to previous studies.  
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In this innovation, such unique nano-assembly has created a 100% therapeutic 
nanomedicine (the excipient free nano-assembly), which means all components function 
as active agents in targeting sides (biofilm). 
Nano-assembly of aminoglycosides is employed by farnesylation of 
aminoglycosides, in which sensitively covalent bonding (e.g. imine, enamine) is formed 
by conjugating equivalent molar ratio of farnesol derivative and amine functional groups 
of aminoglycosides’ molecules, or statistic interaction of farnesol derivative and functional 
groups of aminoglycosides’ molecules. This modification introduces the lipophilic moiety 
into drug molecules. Consequently, the farnesylation of aminoglycosides could 
spontaneously form nano-assembly. Burst release could be avoided, while sustained 
release could be achieved by a chemical linkage which is sensitive to surrounding 
environmental factors at infectious sites, especially to pH gradient in biofilm. 
The main advantages of this innovative platform are as following: (i) A “single step” 
preparation facilitates the dramatic increase in drug loading of aminoglycosides (e.g. 
Tobramycin) up to 70%, and of both aminoglycosides and quorum sensing inhibitory 
farnesol derivatives up to 100%. Notably, the ‘Aminoglycosides nano-assembly’ in this 
innovation is 100% therapeutic nano-medicine (the excipient free nano-assembly). (ii) 
Farnesol derivatives are small molecules, and they enable the stable self-assembly 
complexes. Hence, the drug loading capacity is much higher compared to conventional 
encapsulation strategies and Squalenoylation approach. Moreover, aminoglycosides are 
generally highly charged molecules; hence, their conjugation with capably assembling 
molecules (e.g. squalene derivatives) would result in insoluble products in common 
solvents. However, in this innovation, the farnesylation of aminoglycosides does not cause 
such problem, and the nano-assembly could be effortlessly formed. Structure of 
tobramycin nano-assembly by farnesylation in nano-size and spherical shape has been 
convincingly proved by Cryo-TEM image shown in Figure 1. 
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Figure 1. Cryo-TEM image of the farnesyl-conjugated tobramycin nano-assemblies.  
(iii) “Dual functioned” nanomedicines due to the presence of farnesyl derivatives’ quorum 
sensing inhibiting activity increases anti-microbial activities of the nano-medicine 
‘Aminoglycosides nano-assembly’. The quorum sensing inhibitory effects of farnesyl 
derivatives are summarized in Table 1. Notably, the farnesyl hydrogen sulfate derivative 
performed impressively improvement in inhibiting pyocyanin production of PA14 wt, which 
would be explained by the self-assembly of such derivative in comparison to non-water-
soluble phase of farnesol or farnesal. The self-assemblies of farnesyl hydrogen sulfate 
are observed by Cryo-TEM, and a representative image is presented in Figure 2. (iv) The 
introduction of lipophilic moieties, Farnesol derivatives, can improve the penetration of 
aminoglycosides through bacteria cell walls. Moreover, the presence of lipophilic moieties 
by chemical linkage or statistic interaction strongly decreases charge of aminoglycosides 
molecules; as a result, the modified aminoglycosides in this innovation do not have strong 
interaction with biological barriers like mucus, biofilm, and penetrate faster through such 
barriers. The hypothesis is fully proved by the results obtained from MBEC assays shown 
in Figure 3. Moreover, the incorporation of either fanesal, farnesol or farnesyl hydrogen 
sulfate with tobramycin into the nano-assemblies enhances significantly the efficacy 
against PA14 wt biofilm. Although the pyocyanin inhibiting effects of both farnesol and 
fanesal could not be determined at the tested concentration, the complementary effects 
with antibiotics of these two natural-lipid-based quorum sensing inhibitors were clearly 
shown when being assembled into the nano-assemblies. (v) The formulation avoids burst 
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release of aminoglycosides by sensitive (e.g. pH) chemical linkages (e.g. imine, enamine) 
of farnesol derivatives and aminoglycosides, or statistic interaction of farnesol derivatives 
and aminoglycosides. (vi) The rich positively charged surface of aminoglycosides nano-
assembly stabilizes really well such carrier system, and could also be used for further 
surface modification, while the hydrophobic core would be also further employed to load 
hydrophobic compounds, which altogether makes great innovation of multiple drugs 
delivery systems. 
Table 1. Pyocyanin inhibiting efficacy on PA14 wt of farnesyl derivatives (a) 
Farnesyl 
derivatives 
Function in the 
innovative 
nanoassemblies 
Stock solvent 
for 
solubilization 
EC50 of 
pyocyanin 
inhibiting level 
(µg/mL) 
Farnesal 
Farnesylation of 
aminoglycosides based on 
pH sensitive chemical 
linkage, and function as a 
QSI 
Ethanol N/A (b) 
Farnesol Function as a QSI Ethanol N/A (b) 
Farnesyl hydrogen 
sulfate 
Farnesylation of 
aminoglycosides based on 
charge interaction, and 
function as a QSI 
Ethanol ~10 
 
(a) The inhibition of pyocyanin level on PA14 wt strain after being treated with either farnesal, farnesol or 
farnesyl hydrogen sulfate was measured compared to untreated PA14 wt control. All PA14 wt bacteria 
samples were grown in PPGAS. At least three independent experiments performed in triplicate each. 
(b) N/A: not available. The EC50 values of farnesal and farnesol were not determined. The inhibitory level of 
both compounds was lower than 50% at the highest tested concentration of 30 µg/mL.  
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Figure 2. Cryo-TEM image of farnesyl hydrogen sulfate nanoassemblies in aqueous solution 
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Figure 3. Minimum Biofilm Eradicating Concentration Assay. 
PA14 wt biofilm grown in PPGAS for 24h (starting OD600=3.0) were treated with A) Tobramycin (Tob); B) 
Tob-Farnesal nanoassemblies; C) Tob-Farnesal & Farnesol nanoassemblies; D) Tob-Farnesal and 
Farnesyl hydrogen sulfate nanoassemblies. The total concentration of farnesyl QSI was kept constant at 
100 µg/mL in all experiments treated with QSI. After 24h incubation, efficacy was assessed by determination 
of cfu/mL. Cfu/mL values are depicted logarithmically for n = 3 experiments with technical triplicates each. 
PA14 wt biofilm samples served as controls. The dotted line indicates the detection limit. Significant different 
shown at level *p<0.001 compared to controls; #p<0.001 compared to samples treated with Tob 3.125 
µg/mL; §p<0.001 compared to samples treated with Tob 6.25 µg/mL; and &p<0.001 compared to samples 
treated with Tob 12.5 µg/mL. 
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